Home  »  Companies   »  Are You Looking For A Good Stock? Here’s An ...

Are You Looking For A Good Stock? Here’s An Analysis Of Xeris Biopharma Holdings Inc (NASDAQ: XERS)

Xeris Biopharma Holdings Inc (NASDAQ:XERS) price closed higher on Friday, February 09, jumping 2.87% below its previous close.

A look at the daily price movement shows that the last close reads $4.60. The company’s 5Y monthly beta was ticking 1.11. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.07 and 52-week low of $1.11. The stock added 2.50% on its value in the past month.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Xeris Biopharma Holdings Inc, which has a market valuation of $396.40 million, is expected to release its quarterly earnings report Mar 04, 2024 – Mar 08, 2024. Analysts tracking XERS have forecast the quarterly EPS to shrink by -0.1 per share this quarter, while the same analysts predict the annual EPS to hit -$0.43 for the year 2024 and up to -$0.27 for 2024. In this case, analysts estimate an annual EPS growth of 38.60% for the year and 37.20% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $43.55 million, with the likely lows of $42.02 million and highs of $45.5 million. The average estimate suggests sales growth for the quarter will likely rise by 31.40% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $162.62 million for the company’s annual revenue in 2023. Per this projection, the revenue is forecast to grow 47.50% above that which the company brought in 2023.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 1 upward and — downward reviews. On the technical perspective front, indicators give XERS a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.

The overview shows that XERS’s price is at present 13.96% off the SMA20 and 62.56% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 65.34, with weekly volatility standing at 5.61%. The indicator jumps to 6.29% when calculated based on the past 30 days. Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s beta value is holding at 1.62, while the average true range (ATR) indicator is currently reading 0.15.

Turning out attention to how the Xeris Biopharma Holdings Inc stock has performed in comparison to its peers in the industry, here’s what we find: XERS’s stock is 2.87% on the day and 151.75% in the past 12 months. Turning out attention to how the Xeris Biopharma Holdings Inc stock has performed in comparison to its peers in the industry, here’s what we find: XERS’s stock is 2.87% on the day and 151.75% in the past 12 months. Another comparison is with Eli Lilly & Co. (LLY) whose stock price was up 0.61%% in the last trading session, and has flourished 111.23% over the past year.

An analysis of the Xeris Biopharma Holdings Inc (NASDAQ:XERS) stock in terms of its daily trading volume indicates that the 3-month average is 1.06. However, this figure increases on the past 10-day timeline to an average of 1.46 million.

Current records show that the company has 136.27M in outstanding shares. The insiders’ percentage holdings are 10.71% of outstanding shares while the percentage share held by institutions stands at 38.80%. The stats also highlight that short interest as of Jan 31, 2024, stood at 9.4 million shares, which puts the short ratio at the time at 3.47. From this we can glean that short interest is 6.80% of company’s current outstanding shares. Notably, we see that shares short in January fall slightly given the previous month’s figure stood at 9.61 million. But the 22.13% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.